Macter International Ltd. · PSX:MACTER
Macter International — Investor Presentation (November 2025)
11 slides from Macter International's investor presentation, Nov 10, 2025
Slide 1: Letter to Pakistan Stock Exchange on Corporate Briefing Session
November 7, 2025 The General Manager Pakistan Stock Exchange Limited Stock Exchange Building, Stock Exchange Road, Karachi Subject: Corporate Briefing Session of Macter International Limited Dear Sir, Further to our letter dated November 3, 2025 on the above subject, please find attached herewith pr
Slide 2: Corporate Briefing Session
Corporate Briefing Session November 10, 2025
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL ANY SECURITIES OR ANY INVESTMENT This presentation has been prepared by Macter International Limited (“Macter”) solely for information purposes. No representation or warranty express or implied is made thereto, a
Slide 4: About Macter, Mission and Vision
CORPORATE HIGHLIGHTS COMPANY INFORMATION About Macter Macter International Limited is among the leading Pharmaceutical companies in Pakistan with a successful track record of 30 years. Our key manufacturing areas are MDI, DPI, cephalosporin, and biologicals including recently commissioned Pre-Filled
Slide 5: Financial Highlights
Macter FINANCIAL HIGHLIGHTS
Slide 6: Financial Highlights FY 2022-23 to FY 24-25
FINANCIAL HIGHLIGHTS Particulars FY 2022-23 FY 2023-24 FY 2024-25 Sales 6,680 7,535 9,914 Gross Profit 2,785 3,182 4,458 Gross Margin 42% 42% 45% Operating Profit 618 713 1,234 Profit After Tax 393 427 738 EPS 8.58 9.32 16.10
Slide 7: Financial Highlights Q1 2025-26
FINANCIAL HIGHLIGHTS Particulars Q1 2025-26 Q1 2024-25 Growth Sales Net turnover for the period ended September 30, 2025, was Rupees 2,769 million with a growth of 28%. Sales 2,769 2,165 28% All revenue categories (prescription, institution and export) registered double-digit growth. The profit leve
Slide 8: Corporate Highlights
CORPORATE HIGHLIGHTS
Slide 9: New Manufacturing Facility: PFS and PFP
NEW MANUFACTURING FACILITY PRE-FILLED SYRINGE (PFS) & Pre-filled Pen (PFP) FACILITIES Macter has successfully commissioned and obtained the requisite licenses for its Pre-Filled Syringe (PFS) and Pre-Filled Pen (PFP) manufacturing facilities. Macter now has the capability to manufacture all three bi
Slide 10: New Launch: Semaglutide PFS and PFP
NEW LAUNCH SEMAGLUTIDE - PRE-FILLED SYRINGE (PFS) AND PRE-FILLED MULTI-DOSE PEN (PFP) Semaglutide - Glucagon-Like Peptide-1 (GLP-1) receptor agonist, a class of drugs widely used in the management of Type 2 Diabetes Mellitus and increasingly recognized for its role in weight management and metabolic
Slide 11: Thank You, Q & A Session
Thank You Q & A Session
Macter International — Investor Presentation (November 2025) on 6ix